Tyche Wealth Partners LLC Has $213,000 Stock Holdings in Regulus Therapeutics Inc. (NASDAQ:RGLS)

Tyche Wealth Partners LLC boosted its position in shares of Regulus Therapeutics Inc. (NASDAQ:RGLS) by 14.6% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 121,589 shares of the biopharmaceutical company’s stock after acquiring an additional 15,500 shares during the period. Tyche Wealth Partners LLC owned approximately 0.18% of Regulus Therapeutics worth $213,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. PEAK6 LLC acquired a new stake in shares of Regulus Therapeutics during the 4th quarter worth approximately $95,000. Oppenheimer & Co. Inc. acquired a new position in shares of Regulus Therapeutics in the first quarter valued at $96,000. Velan Capital Investment Management LP bought a new position in Regulus Therapeutics in the fourth quarter worth $111,000. Barclays PLC boosted its stake in Regulus Therapeutics by 13.9% during the fourth quarter. Barclays PLC now owns 96,247 shares of the biopharmaceutical company’s stock worth $152,000 after buying an additional 11,770 shares in the last quarter. Finally, Renaissance Technologies LLC boosted its stake in Regulus Therapeutics by 20.5% during the fourth quarter. Renaissance Technologies LLC now owns 117,100 shares of the biopharmaceutical company’s stock worth $185,000 after buying an additional 19,900 shares in the last quarter. 92.38% of the stock is currently owned by institutional investors.

Insider Activity

In related news, insider Preston Klassen bought 12,000 shares of Regulus Therapeutics stock in a transaction dated Tuesday, June 3rd. The shares were bought at an average cost of $7.99 per share, for a total transaction of $95,880.00. Following the completion of the transaction, the insider now owns 48,055 shares of the company’s stock, valued at approximately $383,959.45. This trade represents a 33.28% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 4.35% of the stock is currently owned by corporate insiders.

Regulus Therapeutics Trading Down 1.3%

NASDAQ RGLS opened at $8.04 on Thursday. Regulus Therapeutics Inc. has a 1-year low of $0.83 and a 1-year high of $8.35. The company has a 50 day moving average of $7.02 and a 200-day moving average of $3.36. The firm has a market cap of $556.26 million, a price-to-earnings ratio of -11.01 and a beta of 0.35.

Regulus Therapeutics (NASDAQ:RGLS) last released its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.14. On average, analysts forecast that Regulus Therapeutics Inc. will post -0.88 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the stock. Leerink Partners reaffirmed a “market perform” rating and set a $7.00 price objective on shares of Regulus Therapeutics in a report on Wednesday, April 30th. Wells Fargo & Company reissued an “equal weight” rating and issued a $9.00 price target on shares of Regulus Therapeutics in a research report on Thursday, May 1st. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price objective on shares of Regulus Therapeutics in a report on Friday, March 14th. Leerink Partnrs lowered Regulus Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, April 30th. Finally, Wall Street Zen assumed coverage on Regulus Therapeutics in a report on Sunday, May 18th. They issued a “sell” rating for the company. One analyst has rated the stock with a sell rating, five have issued a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat, Regulus Therapeutics presently has a consensus rating of “Hold” and an average target price of $8.50.

Regulus Therapeutics Profile

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.